Categories: News

The Adecco Group introduces the agility advantage to grow, adapt and lead in the intelligent era

  • Agility advantage enables human and business agility across talent and technology solutions
  • Strengthen run: enhancing commercial and operational excellence to drive profitable growth
  • Accelerate change: innovate and transform, scaling digital platforms and pioneering a human-centric AI agenda to unlock new efficiencies and growth levers
  • Enterprise intelligence company, r.Potential demonstrates future of strategic workforce management for hybrid human and digital workforces
  • Long term financial framework confirmed – reiterating commitment to 3-6% margin corridor and leverage at or below 1.5x by end 2027

LONDON, Nov. 26, 2025 /PRNewswire/ — The Adecco Group (SIX: ADEN), the leading talent and technology advisory company, will unveil how it creates an agility advantage for organizations, human and digital workers in the face of ongoing technology and demographic shifts. At its Capital Markets Day in London the Group will outline its value creation path, shaping the future of work in the intelligent era.

- Advertisement -

Denis Machuel, CEO, the Adecco Group, said: We have proven our ability to execute and gain share. We are strongly positioned to build on our market-leading positions, with Adecco, Akkodis and LHH, and continue our value creation path in the intelligent era.

- Advertisement -

“Today we set out our agility advantage value creation path – delivered through a run-and-change model. To strengthen run, we will build on our strong execution track record to drive further profitable growth and share gains. To accelerate change, we will further scale our digital platform; be a pioneer in generative and agentic AI; and shape the future of hybrid human and digital workforces with our joint venture, r.Potential.

- Advertisement -

“Our financial commitments are reconfirmed, with a financial strategy focused on maximizing EBITA and deleveraging.”

- Advertisement -

Read full press release here.

- Advertisement -

https://www.adeccogroup.com/our-group/media/press-releases/the-adecco-group-introduces-the-agility-advantage-to-grow-adapt-and-lead-in-the-intelligent-era

- Advertisement -

About The Adecco Group

- Advertisement -

The Adecco Group is the world’s leading talent and technology expertise company. Our purpose is making the future work for everyone. Through our three global business units – Adecco, Akkodis and LHH – across 60 countries, we enable sustainable and lifelong employability for individuals, deliver digital and engineering consulting solutions to power transformation and empower organisations to optimise their workforces. The Adecco Group leads by example and is committed to fostering sustainable employability and supporting resilient economies and communities. The Adecco Group AG is headquartered in Zurich, Switzerland (ISIN: CH0012138605) and listed on the SIX Swiss Exchange (ADEN).
https://www.adeccogroup.com/

- Advertisement -

Logo – https://mma.prnewswire.com/media/2608173/5642745/The_Adecco_Group_Logo.jpg

- Advertisement -

For further information please contact:

- Advertisement -

The Adecco Group Corporate Press Office
Jürg Schneider
Group Head External Communications, The Adecco Group
media@adeccogroup.com

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/the-adecco-group-introduces-the-agility-advantage-to-grow-adapt-and-lead-in-the-intelligent-era-302626210.html

- Advertisement -

Recent Posts

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI…

42 minutes ago

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

June 13, 2026 07:30 ET  | Source: Intellia Therapeutics, Inc. Data from HAELO Phase 3…

42 minutes ago

New TALVEY(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

TALVEY® plus daratumumab with or without pomalidomide showed progression-free survival of up to 81.3% and overall survival of…

42 minutes ago

President Droupadi Murmu Confers Kirti Chakra on Chandigarh University Alumnus Major Arshdeep Singh Gill

"Chandigarh University not only provides quality education but also instills a spirit of patriotism," says…

3 hours ago

Bitmine Immersion Technologies Announces Initial Dividends and NYSE Listing for Series A Preferred Stock

Bitmine's Board of Directors declares initial cash dividends on the Company's 9.50% Series A Perpetual…

5 hours ago

Relativity Acquires Gavel to Extend its AI Platform for Legal Data Intelligence into Microsoft Word

News Summary:Relativity has acquired Gavel, an AI-native legal technology company whose solutions are used by…

5 hours ago